Summit Announces PhaseOut DMD Did Not Meet Primary Endpoint
27. Juni 2018 07:00 ET
|
Summit Therapeutics plc
Ezutromid Development to be DiscontinuedSummit to Focus on Advancing its Pipeline of New Mechanism AntibioticsConference Call Scheduled for 8:00am EDT / 1:00pm BST OXFORD, United Kingdom and...
Summit Announces New Analysis Showing Ezutromid Significantly Reduced Muscle Inflammation in Phase 2 Clinical Trial in DMD
26. Februar 2018 07:00 ET
|
Summit Therapeutics plc
MRS-T2 Data Provide Evidence of Early Impact of Ezutromid on Downstream Muscle HealthData Build on Positive Biopsy Findings that Showed Significant Decrease in Muscle Damage OXFORD, United Kingdom,...
Ezutromid Significantly Reduced Muscle Damage in DMD Patients in 24-Week Interim Data From Summit’s PhaseOut DMD Clinical Trial
25. Januar 2018 07:00 ET
|
Summit Therapeutics plc
Increase in Utrophin Protein Expression ObservedSummit Accelerating Preparations for Pivotal Clinical TrialEzutromid is a Potential Disease-Modifying Treatment for the Entire DMD Patient...
Santhera Pharmaceuticals, Summit Therapeutics, Catabasis Pharmaceuticals and Duchenne UK to host Duchenne Muscular Dystrophy Awareness Day
06. Dezember 2017 02:00 ET
|
Summit Therapeutics plc
LIESTAL, Switzerland, OXFORD, England and CAMBRIDGE, Mass., Dec. 06, 2017 (GLOBE NEWSWIRE) -- Santhera Pharmaceuticals (SIX:SANN), Summit Therapeutics (NASDAQ:SMMT) (AIM:SUMM), Catabasis...
Summit Highlights Utrophin Modulation as a Potential Universal Treatment Option in DMD at 15th Action Duchenne International Conference
09. November 2017 07:00 ET
|
Summit Therapeutics plc
New Preclinical Data Show Utrophin’s Positive Effect on Mitochondria Improving Muscle Health in DMD Model OXFORD, United Kingdom, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc...
Summit Highlights DMD Biomarker Validation Data and Phase 2 Clinical Trial Baseline Characteristics in Presentations at 22nd WMS Congress
04. Oktober 2017 07:00 ET
|
Summit Therapeutics PLC
OXFORD, United Kingdom, Oct. 04, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Joins cTAP in Collaborative Effort to Enhance the Development of Utrophin Modulators and Other Treatments for Duchenne Muscular Dystrophy
25. September 2017 07:00 ET
|
Summit Therapeutics PLC
OXFORD, United Kingdom, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT)(AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Presents Data From Phase 1 Clinical Programme of Ezutromid at the European Paediatric Neurology Society Congress
22. Juni 2017 07:00 ET
|
Summit Therapeutics PLC
OXFORD, United Kingdom, June 22, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Enrols Patients in the United States Into PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Patients With DMD
16. November 2016 07:00 ET
|
Summit Therapeutics PLC
OXFORD, United Kingdom, Nov. 16, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Therapeutics Presents Preclinical DMD Data at the 21st International Congress of the World Muscle Society
06. Oktober 2016 07:00 ET
|
Summit Therapeutics PLC
Summit reports on development of new, automated biomarker tools to evaluate disease status of muscle biopsies OXFORD, United Kingdom, Oct. 06, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc...